echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The multi-billion-dollar chronic cough market is vacant with P2X3 antagonists coming

    The multi-billion-dollar chronic cough market is vacant with P2X3 antagonists coming

    • Last Update: 2021-10-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Author: Clover

    On October 8, China Biopharmaceuticals issued a corporate announcement stating that the company's self-developed innovative drug "TCR1672" had submitted an investigational new drug (IND) application to the U.


    According to the announcement, TCR1672 is a second-generation highly selective P2X3 receptor antagonist, currently mainly used in the treatment of refractory chronic cough (RCC) adult patients in the respiratory field and endometriosis in the pain field and other complex internal organs Pain patients


    What is a P2X3 receptor antagonist?

    What is a P2X3 receptor antagonist?

    It is reported that in 1996, Pelleg and Hurt proved for the first time that extracellular ATP is an effective activator of sensory nerve fibers of the canine lung vagus nerve.


    Image source: Bellus Health

    Some structural/anatomical evidence suggests that cough reflex hypersensitivity may be specifically mediated through P2X3 receptors, which are ligand-gated ion channels in the purinergic receptor family


    Therefore, antagonists that target P2X3 homotrimers have a therapeutic effect by blocking the influx of calcium ions produced by the P2X3 receptor initiated by adenosine triphosphate (ATP), thereby exerting a specific inhibitory effect on it


    What is the market prospect and commercial value?

    What is the market prospect and commercial value?

    According to public data, about 5%-10% of adults worldwide suffer from chronic cough


    According to a Bellus Health corporate report, there are approximately 2.


    It is worth mentioning that according to Yaozhi data query, as of now, there is no clinically approved standard drug for the treatment of chronic cough, and there are huge unmet clinical needs


    Therefore, P2X3 receptor blockers are expected to become the first type of targeted therapy drugs for the treatment of refractory chronic cough (RCC) or unexplained chronic cough (UCC); it will become the most potential refractory cough in recent decades Therapeutic drugs for asthma


    Who will eat the "crab" first?

    Who will eat the "crab" first?

    Although there is no P2X3 inhibitor approved globally, the P2X3 target has become a popular research target in recent years, and domestic and foreign companies have deployed them


    Research progress of some P2X3 inhibitors at home and abroad

    Among them, Merck’s gefapixant (MK-7264) has made the fastest research progress.


    Data deadline: February 2020

    Image source: Bellus Health

    Gefapixant (MK-7264) was acquired by Merck in 2016 with a USD 1.


    Speaking of this, I have to mention the P2X3 receptor selective antagonist QR052107B independently developed by China's Wuhan Langlai Technology, which is also a highly selective P2X3 receptor antagonist, which is on the premise of retaining good antitussive efficacy.


    In addition, Bayer also announced in September that its IIb clinical study of eliapixant (BAY1817080) for the treatment of patients with refractory chronic cough (RCC) reached the primary endpoint


    Note: The original text has been deleted

    references:

    1.


    2.


    3.
    https://ir.
    bellushealth.
    com/static-files/e26b65d5-50fb-483c-91d0-8a5c3b138cbb

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.